Dasatinib

Catalog No.S1021 Synonyms: BMS-354825

Dasatinib Chemical Structure

Molecular Weight(MW): 488.01

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 147 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 73 Publications

13 Customer Reviews

  • Antitumor activity (A)and body weight (B) relationship for BLU-285 and dasatinib in a P815 KIT D814Y mastocytoma allograft model.

    Science, 2017, 9(414), doi: 10.1126/scitranslmed.aao1690. Dasatinib purchased from Selleck.

    Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta.

    Cell Res 2011 21, 1080-1087. Dasatinib purchased from Selleck.

  • Cytotoxicity by Dasatinib and Nutlin-3 used alone or in combination in B-CLL patient leukemic cells. B-CLL patient leukemic cells were exposed to serial doses of Dasatinib or Nutlin- 3 used either alone or in combination, with a fixed ratio, for 48 hours. Dose-effect plots, to determine drug efficacy, are shown for representative B-CLL samples, including 3 patients carrying 17p- (Pt. #7, Pt. #8, and Pt. #10). The decrease of cell viability, labeled "effect" on the Y-axis, was determined in assays done at least twice in duplicate.

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

    Dasatinib interferes with the p53 transcriptional activity induced by Nutlin-3. Leukemic cell lines were exposed for 24 hours to Dasatinib (10 μM) and Nutlin-3 (10 μM), used either alone or in combination, as indicated. Levels of p53 (A), MDM2 and p21 (B) were assessed by Western blot analysis of total cell lysates. Representative examples of Western blot results are shown. Tubulin staining is shown as loading control; after densitometric analyses, p53 as well as MDM2 and p21 protein levels are expressed as folds of protein modulation, by the indicated treatments, with respect to the control untreated cultures set to 1 (hatched line). *P < 0.05 with respect to the Nutlin-3-treated cultures.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

  • Role of Akt in Dasatinib cytotoxicity and in DasatinibtNutlin-3 synergy. A, whole cell lysates were prepared from EHEB and BJAB cell lines treated (for 16 hours) as indicated, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls (set at 100) on the same membrane. The analysis of modulation of phosphorylation signals for P-ERK1/2, P-p38, and P-Akt are reported (*P < 0.05). Validation of phospho-kinase array results was carried out by Western blot analysis of P-Akt levels.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

    Impact of the TKI erlotinib, lapatinib, dasatinib, and sorafenib on the viability of MDS/AML cells. MOLM-13 (A) and HL-60 (B) cells were incubated with the indicated doses (given in mM below the x-axis) of the 4 TKI, and cellular viability was assessed by MTT assay after 24, 48 and 72 h of incubation. Changes in viability are given as percentage of cells as compared to non-treated control samples. This experiment was repeated at least three times, yielding comparable results. Graphs show representative results of one experiment carried out in duplicates (mean standard deviation).

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

  • Capacity of the TKI to overcome the AML-typical differentiation blockage. The myeloid cell lines MOLM-13 and HL-60 were incubated for 6 days with 0.01% DMSO (serving as a negative solvent control), 1 μM of ATRA (serving as a positive control), as well as with the indicated doses of the four TKI. (A) Representative May -Gruenwald -Giemsa staining of MOLM-13 cells, (B) quantitation of the percentage of MOLM-13 cells exhibiting at least two morphological signs of differentiation (that is a decrease in cytoplasmic basophilia, a reduction of the nucleo-cytoplasmic ratio, appearance of nuclear lobulation and/or cytoplasmic granules). Percentages were evaluated by examining at least 100 cells/condition; (C) representative FACS overlays of MOLM-13 cells depicting TKI-induced CD11b expression (black line) as compared to the isotype (shaded grey); (D) quantitation of TKI-induced CD11b-expression in MOLM-13 cells; (E) representative slides depicting morphology/staining of MOLM-13 cells assessed in the NBT-reduction assay; (F) respective quantitative assessment demonstrating the NBT-reducing capacity under the different drugs; (G) representative May-Gruenwald-Giemsa staining of HL-60 cells.

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

    Cytotoxicity by Dasatinib treatment in leukemic cells.Leukemic cell lines were exposed to Dasatinib (10 μM). Upon treatment, cell viability (a) was calculated as percentage with respect to the control vehicle cultures (set to 100% for each cell line) and induction of apoptosis (b) was calculated as percentage of Annexin V+/PI+ cells after 48 h of treatment.

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Human phospho-kinase array analysis in response to Dasatinib treatment. Whole cell lysates were prepared from EHEB (p53wt) and BJAB (p53mut) B cell lines, either left untreated or exposed to Dasatinib for 24 h, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls on the same membrane. In a, intense decreases of signal of P-p38, PERK1/2 and P-CREB in response to Dasatinib are indicated by arrows in the membranes, and intensity of corresponding spots are reported as graphics. In b, analysis of modulation of phosphorylation of STAT family members in response to Dasatinib (spots not shown). The means±SD of three independent experiments are shown. Asterisk indicates P<0.05 against untreated.

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

    Cells were either left untreated (Unt.) or exposed to Dasatinib (Das.) for 24 h. Equal amounts of cell lysates were analyzed for ERK1/2, p38 and CREB phosphorylation by Western blot using antibodies specific for the native form of the kinases and for residues that are phosphorylated (P-) in each kinase upon activation. One of three experimentswith similar results is shown. Protein bands were quantified by densitometry and level of PERK1/2, P-p38 and P-CREB expressed as arbitrary units,were calculated for each cell line after normalization to total ERK1/2, p38 and CREB respectively

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Effect of dasatinib on endothelial cell actin fiber organization. Subconfluent human microvascular endothelial cells‐1 were treated with dimethyl sulfoxide (A) or dasatinib (B), fixed, permeabilized and stained with phalloıdin (green) for F‐actin or FAK (red) for adhesion plaques. Images were taken in a confocal microscope (1000X).

    Cancer Med, 2017, 6(4):809-818. Dasatinib purchased from Selleck.

    Inhibition of cell growth upon culturing of primary bone marrow cells from an EMS patient and a healthy control in presence of TKIs in vitro. EMS cells showed reduced cell growth compared to the healthy control cells when cultured with ponatinib, dovitinb or dasatinib. Cell growth was evaluated after 72 hours in culture. All samples were normalized to DMSO controls. Non-linear regression curves were fitted for evaluation of IC50 values. Error bars represent mean values and standard deviation of the analyzed replicates.

    Eur J Haematol, 2017, 99(5):442-448. Dasatinib purchased from Selleck.

  • Cell vability test result. Different cell lines (A2C12, Beta D5, Gamma A3, Gamma D12, A549, CaCo2,Hep G2) were treated with different concentration of Dasatinib.

     

     

    Dr. Thomas Kruwel of Fraunhofer-Institute for Toxicology and Experimental Medicine-Dasatinib (BMS-354825) purchased from Selleck. Dasatinib purchased from Selleck.

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Description Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.
Targets
Abl [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
c-Kit (D816V) [2]
(Cell-free assay)
c-Kit (wt) [2]
(Cell-free assay)
0.6 nM 0.8 nM 37 nM 79 nM
In vitro

Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. [1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. [3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
M07ep210 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVK5eGc3PzJiaB?= MVXEUXNQ MUjJR|UxRTBwMECwNFch|ryP MWGxO|k2PjB6MB?=
K562 NFr5fnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3adZo4OiCq MYjEUXNQ MnPnTWM2OD1yLkCwNUDPxE1? MkH4NVc6PTZyOEC=
M07e NIDxSZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{X2[FczKGh? M4PyPGROW09? NHLOcWJKSzVyPUCuNFAyOiEQvF2= NVvRWIR7OTd7NU[wPFA>
ALL3 M3vDNmN6fG:2b4jpZ{BCe3OjeR?= MYCwMlHPxE1? MlTiO|IhcA>? M4THO2ROW09? NF;V[lVKSzVyPUCuNFAxPCEQvF2= NVHmWmVQOTl6OEm1OFA>
CML M4\TW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWiyNEBucW5? Mm[ySG1UVw>? MnnZTWM2OD1yLkCwNUDPxE1? NXOxZZZ6OTl{MUmwNVY>
BA/F3 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjJRmFEPzJiaB?= MVnEUXNQ MmnWTWM2OD14LkW4PUDPxE1? NGPJfFkzOzB6OE[0OC=>
BA/F3 MlzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo[wO|IhcA>? Mm\hSG1UVw>? MVnJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzDCZ5IuSWKuIF2zOVFVKG23dHHueEB4cXSqIFnDOVAhd2ZiMD6wNFA5O87:TR?= MUmyN|A5QDZ2NB?=
BA/F3 NYDXW5BvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\lO|FwPzJiaB?= NEThS4xFVVOR NGLnWGhKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlGvSlMh[2WubIOg[ZhxemW|c3nu[{B4cWymIIT5dIUhSmO{LVHicEB4cXSqIFnDOVAhd2ZiMD6wNFQ2|ryP NXjjS2pEOjNyOEi2OFQ>
BA/F3 NE\0d25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXi3NkBp MYPEUXNQ NVLZd3hmUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSmO{LVHicEBVOzF3STDteZRidnRid3n0bEBKSzVyIH;mJFEvPzF2zszN NHflbVYzOzB6OE[0OC=>
BA/F3 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHvWpQ4OiCq MVHEUXNQ MnLMTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTjR6NmOgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNFnPxE1? MofRNlM{ODF5MEO=
BA/F3 NX\SOmpIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUG3NkBp NECxdmhFVVOR M{XkcGlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEV{NUXLJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFMz|ryP MWiyN|MxOTdyMx?=
BA/F3 NUnibmJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfFO|IhcA>? M1rqWWROW09? NWrGeVRUUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiR{K1NGUhdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxPTIQvF2= M4HqfFI{OzBzN{Cz
BA/F3 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\rXVB1PzJiaB?= NUC5R|c1TE2VTx?= MV3JcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBSOjV{SDDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMEC4{txO MlrrNlM{ODF5MEO=
BA/F3 Ml76S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfkO|IhcA>? NH;R[2VFVVOR MUjJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBGOzV7VjDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECxN:69VQ>? MYeyN|MxOTdyMx?=
BA/F3 NWP1[5FJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVG3NkBp MoH0SG1UVw>? MVvJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEKFUj3BRmwh[XO|ZYPz[YQh[XNiZ4Lve5RpKEmwaHnibZRqd25id3n0bEBKSzVyIH;mJFAvODBzOd88US=> NXHGfplrOjN|MEG3NFM>
BA/F3 NV2wT2w2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HJRlczKGh? NHLBc4lFVVOR M1O3dWlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKFl{NUPIJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFI{|ryP MmntNlM{ODF5MEO=
BA/F3 NGDWVXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEftWWc4OiCq M4PWSGROW09? MUHJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBVOzF3STDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDNwNt88US=> MYKyN|MxOTdyMx?=
BA/F3 NXnWc4JXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUC0cWlOPzJiaB?= M2nXcmROW09? NH\0c5VKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCLbnjpZol1cW:wIIfpeIghUUN3MDDv[kAzNjYQvF2= MkTJNlM{ODF5MEO=
T cell M{jwW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUi3NkBp MXTEUXNQ MXfJcohq[mm2czDhcpRqKEOGMz2gZY5lKGGwdHmgR2QzQC2rbnT1Z4VlKFRiY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjByM988US=> NFXjTGoyPzF3NEWxNi=>
WiDr M3\BU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlu3O|IhcA>? MlzuSG1UVw>? MVTJR|UxRTBwMEWyJO69VQ>? MmL5NVU3OTV3MUK=
PC3 NFvoc4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjmO3A4OiCq MUXEUXNQ NFzDc3ZKSzVyPUCuNFA6PCEQvF2= NGPjVZQyPTZzNUWxNi=>
MDA-MB-231 MkHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUC3NkBp NUjPS2NmTE2VTx?= NXz4VWxiUUN3ME2wMlAyOiEQvF2= M4DKR|E2PjF3NUGy
Hs578T NV\VZWdzS3m2b4TvfIlkKEG|c3H5 NHPzNFg4OiCq Mn\TSG1UVw>? MkXiS2k2OD1yLkCzJO69VQ>? MVmyOFAyPTN{Nx?=
HMEC M{jpOmN6fG:2b4jpZ{BCe3OjeR?= NUHuVG1lPzJiaB?= M1nIO2ROW09? M{XnNWdKPTB;MT64JO69VQ>? MXOyOFAyPTN{Nx?=
DU145 M33WcmN6fG:2b4jpZ{BCe3OjeR?= NHv4WXo4OiCq M1PaSmROW09? M4fmUWdKPTB;MD6xOkDPxE1? MXSyOFAyPTN{Nx?=
U251 M2DZeWN6fG:2b4jpZ{BCe3OjeR?= NXvXXolsPzJiaB?= NWK3cmdjTE2VTx?= NWjIWZVLT0l3ME2yMlgyKM7:TR?= MWKyOFAyPTN{Nx?=
NCI60 Mo\HR5l1d3SxeHnjJGF{e2G7 NUPVUnhCPzJiaB?= NWPXToU6TE2VTx?= MVXHTVUxRTVwNzFOwG0> NXPGR5d6OjRyMUWzNlc>
MALME-3M NGHpNZZEgXSxdH;4bYMhSXO|YYm= MYK3NkBp NHy0OoZFVVOR NIi1S5NIUTVyPU[uOlEh|ryP NH7FZoEzPDBzNUOyOy=>
KM12 MWLDfZRwfG:6aXOgRZN{[Xl? MUe3NkBp NF:wbWRFVVOR NX7RTmtyT0l3ME23MlQ1KM7:TR?= MnnmNlQxOTV|Mke=
SW620 NUTo[HFTS3m2b4TvfIlkKEG|c3H5 NX6z[ZlFPzJiaB?= NU\BNGNXTE2VTx?= M2myPWdKPTB;OD60N{DPxE1? MWiyOFAyPTN{Nx?=
RXF 393NL NEe5SndEgXSxdH;4bYMhSXO|YYm= NWm5eHJXPCCmYYnz NFrHd4dFVVOR NV6wZXQyUUN3ME2wMlAzOTdizszN NGCwV5YzOzJ3M{C3OC=>
LXFA 983L MUPDfZRwfG:6aXOgRZN{[Xl? NYn5XINqPCCmYYnz M4Pz[WROW09? NHjvc2NKSzVyPUCuNFU3PSEQvF2= NX\iPHJlOjN{NUOwO|Q>
PRXF DU145 NEP1bGFEgXSxdH;4bYMhSXO|YYm= NES5boI1KGSjeYO= MmnSSG1UVw>? MWXJR|UxRTBwME[yN{DPxE1? M{\FZlI{OjV|MEe0
PAXF 1657L MX;DfZRwfG:6aXOgRZN{[Xl? NILRVGk1KGSjeYO= NFf4PXZFVVOR MoDRTWM2OD1yLkGyNUDPxE1? MX[yN|I2OzB5NB?=
CXF 1103L M1i2RmN6fG:2b4jpZ{BCe3OjeR?= NHHPRoc1KGSjeYO= Mnr1SG1UVw>? MU\JR|UxRTRwM{[g{txO M1nDcFI{OjV|MEe0
GXF251L NWnXc2RHS3m2b4TvfIlkKEG|c3H5 MlfGOEBl[Xm| NVPyXGdHTE2VTx?= MXTJR|UxRTJwMkWg{txO M3:yNFI{OjV|MEe0
NCI-H23 NXTwWVlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX73VYt7PzJiaB?= NXLudGV{TE2VTx?= NIC1eGZKSzVyPUKuNlch|ryP MlXNNlM2OjFyMkC=
HCT116 MlTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUO3XXkzPzJiaB?= M1m0fGROW09? NWracGJKUUN3ME2yMlMh|ryP M17OO|I{PTJzMEKw
MCF7 M3S0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrnO|IhcA>? M4S5OWROW09? MkPTTWM2OD1{LkW3JO69VQ>? NXPxToVuOjN3MkGwNlA>
NCI-H460 NGTkPYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnviO|IhcA>? NXnUXnRVTE2VTx?= MnWyTWM2OD16Lkm5JO69VQ>? NU\lNIlFOjN3MkGwNlA>
DLD1 Mom4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVe3NkBp M2LnXGROW09? NYe1NmhTUUN3ME20MlYh|ryP MmDvNlM2Pjd7NkC=
NCI-H661 NVvzV5VrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU[3NkBp MojQSG1UVw>? NYCxZVRQUUN3ME23Mlgh|ryP MXmyN|U3Pzl4MB?=
A549 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV[3NkBp NWfGN4xMTE2VTx?= MUXJR|UxRThwMjFOwG0> NY\xZ|NPOjN3Nke5OlA>
U937 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYm3NkBp MU\EUXNQ NHnYUZdKSzVyPUGyMlIh|ryP MmfENlM2Pjd7NkC=
HEK293 M3vROmZ2dmO2aX;uJGF{e2G7 MoKxNVDDqM7:TR?= NI\KfYJFVVOR NVTMTnV{UW6mdXPld{BjcW6maX7nJIFn\mmwaYT5JJRwKGi3bXHuJIZ2dGxvbHXu[5RpKEircz30ZYdo\WRiTYn0NUBscW6jc3Wg[ZhxemW|c3XkJIlvKEiHS{K5N{Bk\WyuczD3bZRpKEmFNUCgc4YhOC5yNkROwG0> M1LTNFIzPzdyNkGw
HUVEC Mk[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUewMlE2yqEQvF2= NXTFO2RZPzJiaB?= MX;EUXNQ M{fUOWlv\HWlZYOgZY51cWGwZ3nv[4VvcWNiYXP0bZZqfHliaX6gTHVXTUNiY3:tZ5VtfHW{ZXSge4l1cCC4YYPjeYxieiC|bX;veIghdXW|Y3zlJINmdGy|IHHzd4V{e2WmIHHzJGlvcGmkaYTpc44hd2ZiY3XscEBoem:5dHigZZQhOC5zNTD1US=> NXzPVYdWOjJ6NUO5PVM>
HUVEC MXLGeY5kfGmxbjDBd5NigQ>? MYKxOeKh|ryP NEThdJA4OiCq MnTOSG1UVw>? Ml3STY5lfWOnczDhcpRq[W6paX;n[Y5q[yCjY4Tpeol1gSCrbjDIWXZGSyClbz3jeYx1fXKnZDD3bZRpKH[jc3P1cIFzKHOvb3;0bEBufXOlbHWgZ4VtdHNiYYPz[ZN{\WRiYYOgTY5pcWKrdHnvckBw\iCwZYT3c5JsKG[xcn3heIlwdiCjdDCxMlghfG9iMUWgeW0> MYGyNlg2Ozl7Mx?=
Plasmodium falciparum MnLGSpVv[3Srb36gRZN{[Xl? MVSxNOKh|ryP M1L3WlE2KG2rbh?= M3nr[GROW09? M3S0fWlvcGmkaYTzJHBt[XOvb3TpeY0h\mGuY3nwZZJ2dSCycn;sbYZmemG2aX;uJIJ6KGmwaHnibZRqdmdidHjlJGZ2dmO2aX;uJI9nKFCoQ1TQT|EheHKxdHXpckB4cXSqIFnDOVAhd2ZiMT6xO:69VQ>? NUXwTXVGOjR3NUCzN|A>
PC3 M2rSWWZ2dmO2aX;uJGF{e2G7 NV\2SHRyOC5zIN88US=> MkmyOUBp M1TZc2ROW09? MnXLTY5pcWKrdIOgbJVu[W5iUFOzJINmdGxiYXTo[ZNqd25iYYSgNVAxKG6P NV31Z25rOTl2NkK5O|U>
DU145 MWLGeY5kfGmxbjDBd5NigQ>? MkK5NE4yKM7:TR?= MXS1JIg> NWW5cWxNTE2VTx?= NGjqUpNKdmirYnn0d{BpfW2jbjDEWVE1PSClZXzsJIFlcGW|aX;uJIF1KDFyMDDuUS=> M4W4flE6PDZ{OUe1
PC3 MUnLbY5ie2ViQYPzZZk> NF30PJExNjFizszN MmL3OUBp Mm\CSG1UVw>? MYnJcohq[mm2czDjV5JkKGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YheGixc4Doc5J6dGG2ZXSgV5JkKFl2MU[gcIV3\WxiYYSgNVAxKG6P NIGxSFgyQTR4Mkm3OS=>
DU145 MUHLbY5ie2ViQYPzZZk> Ml7KNE4yKM7:TR?= NEn3R4w2KGh? NU\YWppVTE2VTx?= NGX6ZZpKdmirYnn0d{BkW3KlIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCxZjDwbI9{eGixconsZZRm\CCVcnOgXVQyPiCuZY\lcEBifCBzMECgcm0> Mm\oNVk1PjJ7N{W=
PC3 Mo\MT4lv[XOnIFHzd4F6 NX\OdIdSOC5zIN88US=> MVG1JIg> MmWwSG1UVw>? M4PyfWlvcGmkaYTzJINUemNiaX6gbJVu[W5iUFOzJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBHSUtiWUW3Ok9[PTd5IHzleoVtKGG2IEGwNEBvVQ>? NVT4VIlJOTl2NkK5O|U>
DU145 NH\jd41McW6jc3WgRZN{[Xl? Mlm4NE4yKM7:TR?= NVHu[oxnPSCq NWTuephoTE2VTx?= MYHJcohq[mm2czDjV5JkKGmwIHj1cYFvKESXMUS1JINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBHSUtiWUW3Ok9[PTd5IHzleoVtKGG2IEGwNEBvVQ>? NEG2V3QyQTR4Mkm3OS=>
Huh7 MWHBcpRqfmm{YXygRZN{[Xl? NEOyUnozNjVizszN M{jBfVQh\GG7cx?= NXjQeYxHTE2VTx?= NWq1Zno{UW6qaXLpeJMhfmm{YXygd5Bz\WGmIHnuJGRmdme3ZTD2bZJ2ey2rbn\lZ5Rm\CCqdX3hckBJfWh5IHPlcIx{KGG|c3Xzd4VlKGG|IHHjZ5VufWyjdHnvckBw\iC4aYLhcEBmdn[nbH;w[UBxem:2ZXnuJJdqfGirbjDw[ZJqdnWlbHXhdkBz\Werb36gZZQhOi53IIXN NX;y[WJWOTd|NkC2O|Y>
C6/36 M131fWFvfGm4aYLhcEBCe3OjeR?= MWiyMlUh|ryP NYeyNVJqPCCmYYnz Mnz0SG1UVw>? NV3aW4pRUW6qaXLpeJMhfmm{YXygd5Bz\WGmIHnuJGRmdme3ZTD2bZJ2ey2rbn\lZ5Rm\CCjc3nhckB1cWencjDtc5NyfWm2bzDDOk8{PiClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gc4Yhfmm{YXyg[Y53\WyxcHWgdJJwfGWrbjD3bZRpcW5icHXybY52[2ynYYKgdoVocW:wIHH0JFIvPSC3TR?= NYnCdno6OTd|NkC2O|Y>
U937 NIXIbGhHfW6ldHnvckBCe3OjeR?= MnfINUDPxE1? MUmxJIg> MoKxSG1UVw>? MXXS[YR2[2W|IHLhd4FtKFSQRnHsdIhiKHKnbHXhd4UhcW5iaIXtZY4hXTl|NzDj[Yxtew>? MWexO|Y5PDB7OR?=
U937 MUfGeY5kfGmxbjDBd5NigQ>? MUmxJO69VQ>? NIfj[2QyKGh? NFizeHNFVVOR NF7U[ZVT\WS3Y3XzJGxRWy2rbnT1Z4VlKFSQRnHsdIhiKHKnbHXhd4UhcW5iaIXtZY4hXTl|NzDj[Yxtew>? M1L2OVE4Pjh2MEm5
murine mast cell NWXT[3ZETnWwY4Tpc44hSXO|YYm= MoDZNUDPxE1? MoqwNlQhcA>? MlrHSG1UVw>? MXjJcohq[mm2czDhcpRq\2WwLXnu[JVk\WRiSVy2JJNm[3KndHnvckBqdiCLZ1WgdJJqdWWmIH3veZNmKG2jc4SgZ4VtdHNiYYSgNUB2VQ>? MWqxO|Y5PDB7OR?=
BV-173 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\UUI1lUUN3ME2wMlAxODByMEGwPUDPxE1? M{naPHNCVkeHUh?=
K-562 M2nnN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXRTWM2OD1yLkCwNFAxODJ4NjFOwG0> MXHTRW5ITVJ?
BL-70 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEL5[HhKSzVyPUCuNFAxODByOEKyJO69VQ>? MVXTRW5ITVJ?
EM-2 NIrhXoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37L[2lEPTB;MD6wNFAxODFyODFOwG0> MX;TRW5ITVJ?
LAMA-84 NYXKdY5wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\YUmlEPTB;MD6wNFAxODN{MTFOwG0> MofzV2FPT0WU
MEG-01 NXXucol4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGW3e2FKSzVyPUCuNFAxODB7ODFOwG0> M121OnNCVkeHUh?=
EoL-1-cell MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3jRmtKSzVyPUCuNFAxODF|MTFOwG0> MXzTRW5ITVJ?
CTV-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HzU2lEPTB;MD6wNFAxPDB2IN88US=> NYXSW2ltW0GQR1XS
TE-15 MmD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnywTWM2OD1yLkCwOVg6KM7:TR?= MVzTRW5ITVJ?
NOS-1 NEXocVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHsRodKSzVyPUCuNFA3OTNizszN M{i1fnNCVkeHUh?=
D-336MG MlvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXZVFRKSzVyPUCuNFA3OyEQvF2= NVnudmVZW0GQR1XS
LB1047-RCC M1qz[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrhTWM2OD1yLkCwPVg6KM7:TR?= NXT5VWNwW0GQR1XS
LB996-RCC MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jwZ2lEPTB;MD6wNFk6OSEQvF2= MnjLV2FPT0WU
SW982 M3Hvcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnG2TWM2OD1yLkCxNVE2KM7:TR?= M3i3N3NCVkeHUh?=
TK10 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7MZoxjUUN3ME2wMlAyOTd2IN88US=> NH3JZ3NUSU6JRWK=
A704 NFq2bnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTBwMEG0PVEh|ryP MoCwV2FPT0WU
TE-8 NXjWb4xJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTBwMEG1O|Yh|ryP M4\WNXNCVkeHUh?=
DOHH-2 MoDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV:x[VF7UUN3ME2wMlAyPzF7IN88US=> NIS5[o5USU6JRWK=
HOP-62 NV;EcYs6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXpUZFWUUN3ME2wMlAyQDN2IN88US=> NHPNRpFUSU6JRWK=
TE-12 NWPKU|VVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mne0TWM2OD1yLkCxPFYyKM7:TR?= MV3TRW5ITVJ?
KGN NXXYb3g2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTBwMEG5OFIh|ryP MWPTRW5ITVJ?
NCI-H1648 NYLX[4l3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTBwMEKwNVEh|ryP M13xeHNCVkeHUh?=
OS-RC-2 M1TRfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nMTGlEPTB;MD6wNlA{KM7:TR?= NYrq[lZmW0GQR1XS
GB-1 M16wOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjIc3VKSzVyPUCuNFIyPTdizszN MlznV2FPT0WU
RXF393 NIHjNZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjkTWM2OD1yLkCyN|U4KM7:TR?= MUPTRW5ITVJ?
LC-2-ad MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\iN4pKSzVyPUCuNFI2QDZizszN NWnNSXp2W0GQR1XS
KS-1 NIO3WVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfTT2NzUUN3ME2wMlAzPzNizszN Ml:yV2FPT0WU
ETK-1 M4L6T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\VTWM2OD1yLkCyPFMzKM7:TR?= MkXQV2FPT0WU
SW954 MonFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zJOGlEPTB;MD6wNlkzPyEQvF2= M1vDVnNCVkeHUh?=
Becker M3\ZbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPkTWM2OD1yLkCzNFA{KM7:TR?= NVKyWmNHW0GQR1XS
MZ1-PC M3Hhcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\ocYdEUUN3ME2wMlA{OTF7IN88US=> Mm\sV2FPT0WU
ES6 NF;GXXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfjSlZEUUN3ME2wMlA{OTl|IN88US=> M2i0UnNCVkeHUh?=
KURAMOCHI MojzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTBwMEO0PFch|ryP MUTTRW5ITVJ?
CGTH-W-1 NWjCcFVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWqzfpRpUUN3ME2wMlA{PTR6IN88US=> MljvV2FPT0WU
VA-ES-BJ NWPRSpB2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTVTpJKSzVyPUCuNFM6ODJizszN M3:2[HNCVkeHUh?=
LXF-289 Mo\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTBwMEO5OVYh|ryP MkG3V2FPT0WU
MPP-89 NX24[JBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo[yTWM2OD1yLkC0NFQ6KM7:TR?= NHOwOpFUSU6JRWK=
SW872 NH\IcYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HYUWlEPTB;MD6wOFE3OSEQvF2= MYfTRW5ITVJ?
SNB75 MlHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjhTWM2OD1yLkC0OFM2KM7:TR?= NEHZeIxUSU6JRWK=
PSN1 MojFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWKwRo1qUUN3ME2wMlA1PDd2IN88US=> M17kS3NCVkeHUh?=
LB831-BLC NXLtZlQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnHSGhMUUN3ME2wMlA1PjB7IN88US=> NWT2e2xnW0GQR1XS
MFH-ino MlLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTBwMES3NlQh|ryP NFjt[pRUSU6JRWK=
TGBC24TKB NWLqV2hPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXvTWM2OD1yLkC0O|YyKM7:TR?= NHPJN5ZUSU6JRWK=
A388 NUXaUG9CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTBwMEWwPVUh|ryP NY\yUYlZW0GQR1XS
BB30-HNC M2Xz[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX2zO|lrUUN3ME2wMlA2PDN5IN88US=> MYHTRW5ITVJ?
GI-ME-N NWXNNZBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7tVnlKSzVyPUCuNFYyOThizszN M3L5WnNCVkeHUh?=
TGBC1TKB NYHEdpl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPpV5g3UUN3ME2wMlA3OTZ2IN88US=> NIrXNIZUSU6JRWK=
TE-10 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fCN2lEPTB;MD6wOlM2PyEQvF2= Ml36V2FPT0WU
A498 NYPaVYtCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXMTWM2OD1yLkC3Nlg1KM7:TR?= NFXGTZpUSU6JRWK=
TE-11 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFP3fmRKSzVyPUCuNFc5PThizszN NWnj[mRrW0GQR1XS
BB65-RCC NGHQWYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTBwMEiyNlch|ryP M3OydXNCVkeHUh?=
C2BBe1 M{H1b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jwOmlEPTB;MD6wPFMxQCEQvF2= M1H1T3NCVkeHUh?=
NCI-H747 M4O4PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELNV5JKSzVyPUCuNFg{PjJizszN NELRXHJUSU6JRWK=
IST-MES1 M{XNe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3W3[GlEPTB;MD6wPFU2OiEQvF2= M2jYbHNCVkeHUh?=
KALS-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEOyTY9KSzVyPUCuNFk1QSEQvF2= M4TFbnNCVkeHUh?=
GCIY Ml3SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTBwMEm2OVYh|ryP NGn6[5ZUSU6JRWK=
RL95-2 NWO0cYkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PyTWlEPTB;MD6xNFM5KM7:TR?= MVnTRW5ITVJ?
TE-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFixUFBKSzVyPUCuNVA2PCEQvF2= MoHuV2FPT0WU
NCI-H1355 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTBwMUGwNlgh|ryP NWPQVnRuW0GQR1XS
SW962 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELwSY9KSzVyPUCuNVEzQTJizszN NGLLRopUSU6JRWK=
KLE M{OyeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3MXXdKSzVyPUCuNVE{OTdizszN Mmi2V2FPT0WU
MC116 Mmq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTBwMUG0NUDPxE1? M2\aN3NCVkeHUh?=
NMC-G1 NIrQWIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3f6SmlEPTB;MD6xNVYxPiEQvF2= NEfYPVBUSU6JRWK=
KU812 MlzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTBwMUG4PFMh|ryP M{[ybHNCVkeHUh?=
COLO-829 NV7iNIF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrOTWM2OD1yLkGyNlE{KM7:TR?= NWf4TFJSW0GQR1XS
NTERA-S-cl-D1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPnTWM2OD1yLkGyNlg{KM7:TR?= M3ryWXNCVkeHUh?=
IST-MEL1 NYn5cnJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvsWpAxUUN3ME2wMlE{PDVizszN NXrqTFY3W0GQR1XS
MLMA NV7Ue|lwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vY[GlEPTB;MD6xOFA{OiEQvF2= MX3TRW5ITVJ?
LS-123 MnjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTBwMUSwOlQh|ryP NV7QfHNHW0GQR1XS
LB2518-MEL M371U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLkTWM2OD1yLkG0NVYzKM7:TR?= NXmwenFyW0GQR1XS
NB69 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fBUmlEPTB;MD6xOFQ{PiEQvF2= NVTrO5JKW0GQR1XS
8-MG-BA MnvhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXJeFcxUUN3ME2wMlE2PDV6IN88US=> M{Gz[3NCVkeHUh?=
K5 M1jHbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTBwMU[0PFkh|ryP M{DNOHNCVkeHUh?=
KINGS-1 Mnr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\yR3I4UUN3ME2wMlE3PjZ4IN88US=> M1S4cXNCVkeHUh?=
SF268 M{Lzcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fnUWlEPTB;MD6xO|QxPCEQvF2= M4PCRXNCVkeHUh?=
PF-382 M2\KWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHTU2tkUUN3ME2wMlE4Pjd6IN88US=> MXLTRW5ITVJ?
SH-4 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1H5SGlEPTB;MD6xPFQyOyEQvF2= NH7C[HdUSU6JRWK=
NALM-6 NEP5cWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTz[XVkUUN3ME2wMlE6Ojl3IN88US=> M4nqUHNCVkeHUh?=
CP66-MEL NHTQXG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTBwMUm1N|Eh|ryP NEO4fJBUSU6JRWK=
697 M4TTeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTBwMUm5PFch|ryP NGixeXpUSU6JRWK=
CP67-MEL NUDo[WV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3y4bGlEPTB;MD6yNFQ5QCEQvF2= MmPWV2FPT0WU
DSH1 NVTWNGwyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\MTZZKSzVyPUCuNlQxODFizszN M1jOZ3NCVkeHUh?=
HCE-4 MlHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPjdY1KSzVyPUCuNlY1OzlizszN M2LrW3NCVkeHUh?=
MZ2-MEL MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHhc|BKSzVyPUCuNlg2OzdizszN NGrEVJNUSU6JRWK=
BL-41 NXjoU4xOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{C2fWlEPTB;MD6yPVEzOyEQvF2= M{DCXnNCVkeHUh?=
HUTU-80 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLHc4VTUUN3ME2wMlMyPDJizszN MV\TRW5ITVJ?
LOXIMVI NXPKR3h4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3MNGpKSzVyPUCuN|E2ODNizszN NG[xOJlUSU6JRWK=
no-10 M33aXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjzfppbUUN3ME2wMlMyQTNzIN88US=> NXHVXJhPW0GQR1XS
KARPAS-422 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\E[ZRxUUN3ME2wMlM{QTl5IN88US=> MnvoV2FPT0WU
SW684 MoS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTBwM{S5PEDPxE1? NGiy[FVUSU6JRWK=
SF126 NVPxUm5{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXT3T3ZyUUN3ME2wMlM2PDFizszN NHL5dJVUSU6JRWK=
D-263MG M1ex[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWn0XWlkUUN3ME2wMlM3OjJ2IN88US=> NFfIeGFUSU6JRWK=
OVCAR-4 NXzFUpVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1i0NWlEPTB;MD6zO|Q{OyEQvF2= M13DT3NCVkeHUh?=
BB49-HNC MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTRfGFKSzVyPUCuN|g2QTlizszN Ml\4V2FPT0WU
ONS-76 NXnRbmFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHETWM2OD1yLkSyPVUyKM7:TR?= MVTTRW5ITVJ?
MZ7-mel NVfKUVFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkL4TWM2OD1yLkS3PVEyKM7:TR?= MmPDV2FPT0WU
RCC10RGB MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NISyemZKSzVyPUCuOFkyOSEQvF2= Ml7QV2FPT0WU
BOKU MmX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjkOpFKSzVyPUCuOFkyOzNizszN NInPRXNUSU6JRWK=
no-11 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPWTWM2OD1yLkWwNlI5KM7:TR?= NVPF[2xDW0GQR1XS
IST-SL2 MkeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PqUWlEPTB;MD61NFMxOiEQvF2= MXLTRW5ITVJ?
RKO MnzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTBwNUK5OlYh|ryP M33JZ3NCVkeHUh?=
HT-144 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLtTWM2OD1yLkWzOlA6KM7:TR?= M4PUV3NCVkeHUh?=
NCI-H446 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPnTWM2OD1yLk[yO|Yh|ryP NImxd2dUSU6JRWK=
QIMR-WIL MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnu5TWM2OD1yLkewOlI6KM7:TR?= MV3TRW5ITVJ?
MHH-PREB-1 M2LhSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFf3fnNKSzVyPUCuO|Q1PjlizszN MXLTRW5ITVJ?
EW-16 NVPIRVRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUn1WWFEUUN3ME2wMlc3OTd6IN88US=> M1ruVnNCVkeHUh?=
EW-24 NWPlVWRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVj1dIJzUUN3ME2wMlc5OTZ3IN88US=> NEfaWVVUSU6JRWK=
LB373-MEL-D NETiPYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoS3TWM2OD1yLkiyOVA5KM7:TR?= MWnTRW5ITVJ?
TE-9 NH\TUoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;yTWM2OD1yLki3OVMzKM7:TR?= MlXhV2FPT0WU
A3-KAW MmT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mni5TWM2OD1yLkm4OFUzKM7:TR?= NEjaPZRUSU6JRWK=
A101D M4GySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37LPGlEPTB;MT6wN|A1OyEQvF2= NFTE[I1USU6JRWK=
OCUB-M MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHmwfYJKSzVyPUGuNFQ1OTJizszN NX\iSZZJW0GQR1XS
ES4 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7CcG5RUUN3ME2xMlA2OTR3IN88US=> M2qwNXNCVkeHUh?=
TE-6 MmnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Htd2lEPTB;MT6yNVIzPiEQvF2= MWHTRW5ITVJ?
D-502MG M4WyXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fscWlEPTB;MT6yN|M4PiEQvF2= M2m1UHNCVkeHUh?=
KNS-42 NELSbm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTFwMkS0NVIh|ryP M1jxUXNCVkeHUh?=
SNU-C2B NYDSWoM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFr4fVRKSzVyPUGuN|A2QDlizszN MkHKV2FPT0WU
NCI-H1838 M1f2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXKTWM2OD1zLkOwO|M{KM7:TR?= M{nWcHNCVkeHUh?=
NKM-1 M{jzN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPSdZptUUN3ME2xMlMxQDV7IN88US=> NXXmbIRnW0GQR1XS
GI-1 NH65XI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjKcIdJUUN3ME2xMlM3OjJizszN MlzwV2FPT0WU
NB5 NWjlXFFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TXeWlEPTB;MT6zPVgzPyEQvF2= MmDFV2FPT0WU
CAS-1 Mny2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TX[mlEPTB;MT60NFk6OiEQvF2= M2rSO3NCVkeHUh?=
HCE-T NFT2[phIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTFwNU[3NVQh|ryP MYLTRW5ITVJ?
SBC-1 NWfrdnFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzzTWM2OD1zLkW3PVg1KM7:TR?= NVLOXmNGW0GQR1XS
JiyoyeP-2003 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnXTWM2OD1zLkezOFY3KM7:TR?= NEDN[ZdUSU6JRWK=
TE-5 MnT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jE[GlEPTB;MT63PVE{QSEQvF2= NIHJZpVUSU6JRWK=
CAN NHfZbmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nS[mlEPTB;MT64NlI2OiEQvF2= MXjTRW5ITVJ?
SK-UT-1 M2e5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TKPGlEPTB;Mj6xOlY6OyEQvF2= MlHvV2FPT0WU
JVM-2 MoKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzlTWM2OD1{LkO2Nlg1KM7:TR?= MX3TRW5ITVJ?
LB771-HNC MofGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTJwNUe1OVEh|ryP NEK5VVFUSU6JRWK=
NCCIT MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEK4cYRKSzVyPUKuPFY3OTZizszN MVHTRW5ITVJ?
NCI-H2126 M325T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3:zcGlEPTB;Mj64O|U2OiEQvF2= NI\MN5NUSU6JRWK=
Calu-6 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\uTGlEPTB;Mz6wOVc1OSEQvF2= MoW1V2FPT0WU
SK-LMS-1 Mnz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjNVHdvUUN3ME2zMlEyQDh4IN88US=> MWHTRW5ITVJ?
ARH-77 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DVSGlEPTB;Mz60OlkyPSEQvF2= NULtVYp6W0GQR1XS
NB17 NYrGSVVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmf2TWM2OD1|Lk[zPFQ4KM7:TR?= MWjTRW5ITVJ?
A253 M1HrN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nBTmlEPTB;Mz63N|I1PiEQvF2= MnviV2FPT0WU
OPM-2 NV3XTXBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTRwMke2PFUh|ryP MYLTRW5ITVJ?
MV-4-11 NF\SdY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzyR2FKSzVyPUSuN|Y1PTRizszN NFqy[ZNUSU6JRWK=
SR M4n1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTLN2pKSzVyPUSuOFk6PTRizszN NH\vTZpUSU6JRWK=
KG-1 M2K2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTRwNkC4OFUh|ryP MlTUV2FPT0WU
OCI-AML2 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7LTWM2OD13Lki2NVU1KM7:TR?= NV:5VXJLW0GQR1XS
D-247MG Mo\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTZwMUK1NVkh|ryP M2CzfHNCVkeHUh?=
DJM-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTZwNEi1OVgh|ryP M4Pk[HNCVkeHUh?=
RPMI-6666 MmTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HuR2lEPTB;Nz6yO|A3PyEQvF2= MoPCV2FPT0WU
KARPAS-45 NHzvWJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfNbXlKSzVyPUeuOVE3PzFizszN MnK0V2FPT0WU
LP-1 NGHGU3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjZTWM2OD15LkW0O|gzKM7:TR?= MmTaV2FPT0WU
RS4-11 NX65NIhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TTPGlEPTB;Nz62OVc5PyEQvF2= NWDQ[GxJW0GQR1XS
DU-4475 MnPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLYZWFKSzVyPUiuNlE3PTJizszN Mn;kV2FPT0WU
MONO-MAC-6 MnjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\6PGlEPTB;OD6yO|A3PiEQvF2= MV7TRW5ITVJ?
NCI-SNU-16 MonhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRThwNU[xNlgh|ryP NUPLSWhiW0GQR1XS
SJSA-1 Ml;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXyw[3JXUUN3ME24MlczQDB3IN88US=> MXjTRW5ITVJ?
MMAC-SF Mn;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPNNXNKSzVyPUiuO|k{ODdizszN MmjBV2FPT0WU
SK-NEP-1 Ml[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXQTWM2OD16Lki5NVU2KM7:TR?= M2HJT3NCVkeHUh?=
J-RT3-T3-5 NFnBd5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2mwS2lEPTB;OD65OlUzQSEQvF2= NIH4Z2lUSU6JRWK=
SKM-1 Ml\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYOxVZRyUUN3ME25MlAyPzN2IN88US=> MkPMV2FPT0WU
LB2241-RCC MmPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvVTWM2OD17LkCyNFEzKM7:TR?= NYG2NFE{W0GQR1XS
SIG-M5 M331U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTlwMEK0PVMh|ryP NH22emxUSU6JRWK=
EVSA-T MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLWXIdKSzVyPUmuNlc4QTNizszN Mne0V2FPT0WU
GT3TKB MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fCWmlEPTB;OT6zOVU1PiEQvF2= M1ux[3NCVkeHUh?=
NB6 MoW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTlwOUKyOVkh|ryP NHX5ToJUSU6JRWK=
EHEB MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTFyLkC2OVYh|ryP MlnzV2FPT0WU
HEL MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3y[IV7UUN3ME2xNE41Pzd4IN88US=> MVfTRW5ITVJ?
ALL-PO M1LjUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;VOFlpUUN3ME2xNE44QTN6IN88US=> NE\4Z4lUSU6JRWK=
TGW NUK0SXoyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mne4TWM2OD1zMT6yPFI5KM7:TR?= MoPwV2FPT0WU
BC-3 NHvWVGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjrZm42UUN3ME2xNk4yOTN6IN88US=> M3LoSXNCVkeHUh?=
IA-LM NFz1OIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XaWWlEPTB;MUKuOFQ1PSEQvF2= M{DINXNCVkeHUh?=
UACC-257 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjmb5pKSzVyPUGyMlkyQThizszN NX7NVFI6W0GQR1XS
KP-N-YS MnXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTF{LkmyPFMh|ryP NV;wXJl6W0GQR1XS
Raji MoX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITQdndKSzVyPUGzMlc1QTdizszN NHX1XFlUSU6JRWK=
SF539 M{iyXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\kTWM2OD1zMz64OVU4KM7:TR?= MkO4V2FPT0WU
DMS-153 NUDk[3lTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjwV|VKSzVyPUG0MlAxOjhizszN NHq0W2dUSU6JRWK=
L-540 NIXJcFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTF3LkC2O|Ih|ryP MUPTRW5ITVJ?
MN-60 M{jYNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrOTWM2OD1zNT6xPVc6KM7:TR?= NHHIO4dUSU6JRWK=
RPMI-8866 MoD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXENmhKSzVyPUG3MlQ1PTRizszN NUizcpRuW0GQR1XS
NCI-H510A NGTLOo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHe2N3RKSzVyPUG5MlM6PzNizszN NI\0TJNUSU6JRWK=
NB13 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzPTWM2OD1zOT60PFc4KM7:TR?= MmizV2FPT0WU
HAL-01 MlnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTF7Lke1OFMh|ryP MYDTRW5ITVJ?
NCI-H720 NWi1XHlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTJyLkK3N|Mh|ryP MnfnV2FPT0WU
REH MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jwZ2lEPTB;MkCuOlM2PyEQvF2= M4[2[3NCVkeHUh?=
KNS-81-FD MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTJ|LkG0OkDPxE1? M4rU[3NCVkeHUh?=
HC-1 M{PVSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTJ2LkW1OVEh|ryP MX7TRW5ITVJ?
NCI-H2141 NWr0enhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIf6WWFKSzVyPUK0Mlc4PTRizszN NHHKVnpUSU6JRWK=
MOLT-4 NV3NTZZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nLRmlEPTB;Mk[uOlc2OyEQvF2= NYXX[VNKW0GQR1XS
OMC-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXQTWM2OD1{Nz6xOFIzKM7:TR?= M1;Qc3NCVkeHUh?=
LC-1F NV3a[nB{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;4VWpKSzVyPUK3MlMzPDVizszN MlzaV2FPT0WU
NCI-H1304 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XEOmlEPTB;MkiuNVYzQCEQvF2= M1\vR3NCVkeHUh?=
BC-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTJ6Lk[1NUDPxE1? M1\QXnNCVkeHUh?=
NCI-H64 NG\hRpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jGOGlEPTB;MkmuOlI2OyEQvF2= M13qXXNCVkeHUh?=
MOLT-16 NVLid3RnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTJ7Lk[yPVIh|ryP NX\STI9QW0GQR1XS
U-87-MG NE\CV|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLBT2NKSzVyPUOwMlc3PiEQvF2= MYHTRW5ITVJ?
GAK M4jyUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTNzLkK2PFYh|ryP NXPoVXlCW0GQR1XS
ES8 M3uxbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\4TWM2OD1|Mj6xNlUzKM7:TR?= M4iycHNCVkeHUh?=
HCC1599 M{C0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnxUmZKSzVyPUOyMlM{OjVizszN MXrTRW5ITVJ?
EB-3 NUmzT4NHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTN2LkOxNVch|ryP NIrzTHNUSU6JRWK=
HCC1187 MoLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofzTWM2OD1|NT64NFUzKM7:TR?= M2nMN3NCVkeHUh?=
SK-PN-DW MoPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LmfGlEPTB;M{[uNVk1OyEQvF2= NF\meHpUSU6JRWK=
JVM-3 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITRZXdKSzVyPUO3MlI{OzhizszN MULTRW5ITVJ?
HCC2157 NFPEbmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\Ob3NKSzVyPUO3Mlk6PDZizszN MULTRW5ITVJ?
A4-Fuk NUPaNIVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTN6LkGwNFkh|ryP MkfoV2FPT0WU
COR-L279 M2n6UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17EZmlEPTB;NECuNlg2OSEQvF2= NG\HWnhUSU6JRWK=
DEL M2TCdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfnUmZjUUN3ME20NU46ODh4IN88US=> M2nE[3NCVkeHUh?=
NCI-H1395 M{ewT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TucGlEPTB;NEKuNFE3OyEQvF2= MXrTRW5ITVJ?
MHH-NB-11 NG\HWlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjiTWM2OD12Mz6wPFE5KM7:TR?= NYTB[JlrW0GQR1XS
NCI-H2107 M17ldmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrYTWM2OD12Mz60PFQ3KM7:TR?= MYLTRW5ITVJ?
NEC8 MmHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTmfWRGUUN3ME20OE4{OzZizszN MorLV2FPT0WU
COLO-684 NIS3To1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTR4LkKyOVgh|ryP M2XQZXNCVkeHUh?=
LS-411N NH;xOY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTR6LkS3OFgh|ryP NFXLNYJUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. [3]

Protocol

Kinase Assay:

[1]

+ Expand

Kinase autophosphorylation assays:

Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.
Cell Research:

[1]

+ Expand
  • Cell lines: Ba/F3 cell lines
  • Concentrations: ~32 nM
  • Incubation Time: 72 hours
  • Method:

    Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC)
  • Formulation: DMSO
  • Dosages: 30 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 98 mg/mL (200.81 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 488.01
Formula

C22H26ClN7O2S

CAS No. 302962-49-8
Storage powder
in solvent
Synonyms BMS-354825

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03885830 Not yet recruiting CML Chronic Phase|CML (Chronic Myelogenous Leukemia|CML - Philadelphia Chromosome|Chronic Myeloid Leukemia|Chronic Myeloid Leukemia Chronic Phase UNC Lineberger Comprehensive Cancer Center May 2019 --
NCT03885830 Not yet recruiting CML Chronic Phase|CML (Chronic Myelogenous Leukemia|CML - Philadelphia Chromosome|Chronic Myeloid Leukemia|Chronic Myeloid Leukemia Chronic Phase UNC Lineberger Comprehensive Cancer Center May 2019 --
NCT03878524 Not yet recruiting Breast Cancer|Prostate Cancer|Pancreatic Cancer|Acute Myelogenous Leukemia OHSU Knight Cancer Institute|Oregon Health and Science University|Prospect Creek Foundation March 14 2019 Phase 1
NCT03878524 Not yet recruiting Breast Cancer|Prostate Cancer|Pancreatic Cancer|Acute Myelogenous Leukemia OHSU Knight Cancer Institute|Oregon Health and Science University|Prospect Creek Foundation March 14 2019 Phase 1
NCT03318770 Not yet recruiting Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dell''Adulto December 2018 --
NCT03318770 Not yet recruiting Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dell''Adulto December 2018 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    what’s the difference between S1021 and S7782? Which one is better for in vivo studies?

  • Answer:

    Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).

  • Question 2:

    Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?

  • Answer:

    Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Related Src Products4

Tags: buy Dasatinib | Dasatinib supplier | purchase Dasatinib | Dasatinib cost | Dasatinib manufacturer | order Dasatinib | Dasatinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID